Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Ardelyx’s first-in-class NHE3 blocker Tenapanor boasts positive phase III data

pharmaceutical-technologyMay 27, 2017

Tag: first-in-class , Tenapanor

PharmaSources Customer Service